| 2.65 -0.195 (-6.85%) | 10-14 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 4.7  |
1-year : | 5.72 |
| Resists | First : | 4.02 |
Second : | 4.9 |
| Pivot price | 3.63 |
|||
| Supports | First : | 2.61 |
Second : | 2.17 |
| MAs | MA(5) : | 3.12 |
MA(20) : | 3.74 |
| MA(100) : | 5.54 |
MA(250) : | 4.83  |
|
| MACD | MACD : | -0.5 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 2.9 |
D(3) : | 6 |
| RSI | RSI(14): 25.7 |
|||
| 52-week | High : | 20.31 | Low : | 0.72 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ EDSA ] has closed below the lower bollinger band by 4.2%. Bollinger Bands are 40.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 72 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 2.86 - 2.89 | 2.89 - 2.9 |
| Low: | 2.56 - 2.6 | 2.6 - 2.62 |
| Close: | 2.61 - 2.67 | 2.67 - 2.7 |
Edesa Biotech, Inc. is a biopharmaceutical firm focused on discovering, developing, and commercializing clinical-stage treatments for inflammatory and immune system disorders where current medical options are inadequate. The company's key pipeline assets include EB05, a monoclonal antibody undergoing a Phase 3 clinical trial for acute respiratory distress syndrome (ARDS) in COVID-19 patients, and EB01, a topical therapy in a Phase 2B clinical study addressing chronic allergic contact dermatitis. Furthermore, Edesa has a licensing collaboration with NovImmune SA to advance monoclonal antibodies specifically designed to target TLR4 and CXCL10. This company was established in 2015 and is based in Markham, Canada.
Tue, 06 Oct 2026
A stock award vested in full upon grant gives Edesa Biotech (EDSA) CEO 6,893 shares. - Stock Titan
Tue, 22 Sep 2026
Edesa Biotech (NasdaqCM:EDSA) Stock Forecast & Analyst Predictions - Simply Wall Street
Tue, 01 Sep 2026
Insider share moves at Edesa Biotech (EDSA) detailed in new SEC filing - Stock Titan
Thu, 20 Aug 2026
Edesa Biotech Stock Sinks After Fresh Capital Raise - Yahoo Finance
Wed, 19 Aug 2026
Edesa Biotech Announces Proposed Public Offering - GlobeNewswire
Wed, 19 Aug 2026
Edesa Biotech prices $25M public offering at $5.50 per share - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 14 (M) |
| Shares Float | 7 (M) |
| Held by Insiders | 13.5 (%) |
| Held by Institutions | 37.4 (%) |
| Shares Short | 204 (K) |
| Shares Short P.Month | 245 (K) |
| EPS | -1.65 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.03 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -66.5 % |
| Return on Equity (ttm) | -123 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.08 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -9 (M) |
| Levered Free Cash Flow | -4 (M) |
| PE Ratio | -1.61 |
| PEG Ratio | 0 |
| Price to Book value | 66.25 |
| Price to Sales | 0 |
| Price to Cash Flow | -4.02 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|